Your session is about to expire
← Back to Search
Monoclonal Antibodies
177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma
Phase 1 & 2
Waitlist Available
Research Sponsored by Y-mAbs Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
No Placebo-Only Group
Summary
This trial tests a new treatment for children and adolescents with difficult-to-treat brain cancer. The treatment uses a special antibody combined with radiation to target and kill cancer cells.
Eligible Conditions
- Brain Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Dose Limiting Toxicities (DLTs) Part 1
Secondary study objectives
Absorbed radiation dose of lutetium-177 in blood and cerebrospinal fluid (CSF)
Analysis of lutetium-177 activity in blood
Dosimetry analysis of lutetium-177
+8 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: 177Lu-DTPA-omburtamabExperimental Treatment1 Intervention
Intracerebroventricular administration of 177Lu-DTPA-omburtamab for up to two cycles (Part 1) and up to five cycles (Part 2).
Find a Location
Who is running the clinical trial?
Y-mAbs TherapeuticsLead Sponsor
25 Previous Clinical Trials
1,555 Total Patients Enrolled